Abstract
At the beginning of the COVID-19 pandemic, the extent of the risks of a COVID infection during pregnancy were unknown. During the start of the pandemic, there were only a few studies published comparing outcomes between pregnant women with and without COVID-19 infections. The INTERCOVID study is a large-scale multinational cohort study demonstrating that COVID-19 during pregnancy is associated with significantly higher risks of severe maternal morbidity, mortality, and neonatal complications compared to uninfected pregnant individuals. Even asymptomatic infections carry increased risks for preeclampsia and maternal morbidity, though the highest risks are seen in symptomatic patients, particularly those with fever and shortness of breath.
Introduction
At the onset of the COVID-19 pandemic, clinicians lacked clear data on how the virus affected pregnant individuals and their newborns. While previous coronaviruses like SARS and MERS were known to cause severe complications in pregnancy, early COVID-19 data was limited to small case series without proper control groups.
The researchers sought to fill this gap by conducting a rigorous, comparative study across diverse global settings to determine if COVID-19 independently increases the risk of adverse outcomes like preeclampsia, preterm birth, and neonatal intensive care admission.
Methods
The researchers conducted a prospective, longitudinal, multinational cohort study involving 43 institutions across 18 countries. The study utilized a newly created dataset from the INTERCOVID Multinational Cohort, comprising 2,130 pregnant women (706 with COVID-19 and 1,424 without). Data was collected between March and October 2020 from a wide range of countries, including Argentina, Brazil, Egypt, France, India, Italy, Japan, Mexico, Nigeria, Pakistan, Russia, Spain, Switzerland, the UK, and the US.
Key methodological features included: * Concurrent Enrollment: For every pregnant woman identified with COVID-19 (diagnosed via PCR, ultrasound, or symptoms), two uninfected pregnant women at the same stage of pregnancy and receiving the same level of care were enrolled as a control group. * Standardized Indices: To capture the complexity of outcomes, they used three composite indices: the Maternal Morbidity and Mortality Index (MMMI), the Severe Neonatal Morbidity Index (SNMI), and the Severe Perinatal Morbidity and Mortality Index (SPMMI). * Statistical Modeling: They used Poisson models with a log link function and robust standard errors to calculate Relative Risk (RR), adjusting for variables like country, maternal age, and preexisting conditions.
Key Results and Insights
The study revealed significant disparities in outcomes between infected and uninfected individuals, with severity often tied to the presence of symptoms.
Maternal Morbidity and Mortality
- Maternal Mortality: Women with COVID-19 were 22 times more likely to die (RR 22.3), though the absolute number of deaths was low (11 deaths in the COVID group vs. 1 in the control group).
- ICU Admission: Infected women had a 5-fold increase in the risk of ICU admission (RR 5.04) and stayed nearly 4 days longer in the ICU on average.
- The Preeclampsia Link: One of the most striking findings was the strong association between COVID-19 and preeclampsia/eclampsia (RR 1.76). This suggests that COVID-19 may trigger a systemic inflammatory response that mimics or exacerbates placental dysfunction.
- Asymptomatic Risks: While symptomatic women faced the highest risks, even those who were asymptomatic remained at higher risk for preeclampsia and general maternal morbidity compared to the uninfected group.
Neonatal and Delivery Outcomes
- Gestational Age and Preterm Birth: The increase in preterm births (RR 1.59) was driven primarily by medical necessity (often due to preeclampsia or fetal distress) rather than spontaneous labor. On average, symptomatic COVID-19 led to delivery 0.8 weeks earlier than in uninfected women.
- Neonatal Morbidity: Newborns of infected mothers had a significantly higher Severe Neonatal Morbidity Index (RR 2.66). Approximately 13% of neonates born to COVID-positive mothers also tested positive.
Discussion and Limitations
The INTERCOVID study provides critical evidence that COVID-19 in pregnancy is not a benign condition. However, the authors acknowledge several limitations. Because the study was hospital-based, it may overrepresent more severe cases, as women with mild or no symptoms might not have sought hospital care early in the pandemic. Additionally, testing constraints in the early stages of the study potentially led to some asymptomatic infected women being misclassified into the control group, which would make the reported risks conservative.
Future research is urgently needed to study the long-term health effects on both the parents and the infants. Furthermore, as most participants were in their third trimester, the effects of infection in early pregnancy (first or second trimester) require further dedicated research.
Summary based on JAMA Pediatr 2021;175:817–826.
Summary updated